Mary Beth Nierengarten | Authors

Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs

December 30, 2010

Jeff Kranau’s story is a moving one but, during this economic downturn, not necessarily a unique one. The former South Florida salesman was successfully treated for squamous cell carcinoma of the larynx in 2009 and declared cancerfree. But what should have been a reason for celebration has, over time, sent Mr. Kranau’s life into a tailspin.

SABCS 2010: Providing answers to long-held questions

December 05, 2010

C. Kent Osborne, MD, codirector of SABCS 2010, spoke with Oncology NEWS International about what to watch for at this year’s meeting. Dr. Osborne highlights key studies in adjuvant therapy and aromatase inhibitor therapy and discusses some of the future challenges that the breast cancer community faces.

BRCA Carriers Benefit From Mutations

December 03, 2010

For women with triple-negative breast cancer, BRCA mutations can be a boon: These patients have a significantly lower risk of relapse than their counterparts who do not carry BRCA mutations, according to a study out of Houston’s M.D. Anderson Cancer Center. SABCS 2010 will feature an education session on the clinical utility of genetic testing for inherited predisposition to breast cancer.

Second-Generation TKIs Poised to Succeed Imatinib in Newly Diagnosed CML

August 10, 2010

Imatinib (Gleevec), the first-line standard of care in chronic myeloid leukemia, will become a generic drug in 2015, so the race is on to find a second generation of tyrosine kinase inhibitors (TKIs) that can do the job just as well.

Making comparative effectiveness work in cancer care

August 10, 2010

Patient preference needs to be weighed against overall societal benefits.

ASCO: Selenium fails to prevent secondary lung cancer tumors

July 13, 2010

Results of a long-term intergroup study on the effect of selenium in early non-small-cell lung cancer highlight the differences between smokers and nonsmokers, and support the thesis that “good” supplements may be harmful in the presence of carcinogens.

Eribulin amplifies survival in pretreated metastatic breast cancer patients

July 13, 2010

If approved, oncologists will have a new therapeutic option with proven benefits, acceptable toxicity, said EMBRACE trial leader.